AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesTechnology, Industry, AgricultureInformation ScienceHealth Care
DoxorubicinAntibiotics, AntineoplasticVincristineAntineoplastic Combined Chemotherapy ProtocolsRazoxaneCyclophosphamideAntineoplastic AgentsDrug Resistance, NeoplasmDrug CarriersLiposomesP-GlycoproteinDrug Resistance, MultiplePrednisoneBreast NeoplasmsCell Line, TumorEtoposidePolyethylene GlycolsPaclitaxelVinblastineCisplatinDaunorubicinDrug Administration ScheduleDose-Response Relationship, DrugLeukemia P388CardiotoxinsHydroxyethylrutosideDrug SynergismIfosfamideApoptosisTreatment OutcomeSarcomaTumor Cells, CulturedCombined Modality TherapyAnthracyclinesBleomycinDrug Delivery SystemsDrug ResistanceCell SurvivalDrug Screening Assays, AntitumorMitoxantroneMethotrexateDisease-Free SurvivalSurvival AnalysisInfusions, IntravenousCardiomyopathiesHeart DiseasesVerapamilHeartOsteosarcomaFluorouracilAntineoplastic Agents, PhytogenicTaxoidsDNA Topoisomerases, Type IIMice, NudeChemotherapy, AdjuvantNaphthacenesProcarbazineProdrugsNanocapsulesEpirubicinSurvival RateAclarubicinOvarian NeoplasmsXenograft Model Antitumor AssaysBone NeoplasmsSoft Tissue NeoplasmsNeoplasm TransplantationLung NeoplasmsLeukopeniaTopoisomerase II InhibitorsTime FactorsRemission InductionGenes, MDRMultidrug Resistance-Associated ProteinsNeutropeniaDacarbazineCyclosporinsLymphoma, Non-HodgkinNeoplasmsInhibitory Concentration 50MechlorethamineLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, Murine-DerivedGranulocyte Colony-Stimulating FactorMyocardiumTissue DistributionNeoplasm StagingHodgkin DiseaseEyelidsNanoparticlesDNA DamageCarcinoma, Small Cell
CyclophosphamideVincristineCisplatinChemotherapyStudied the effect of doxorubicinPaclitaxelLiposomal doxorubicinConjugateIfosfamideHepatocellular carcinomaAnticancerPatientsAntitumorChemotherapeutic agentsCyclesLymphomaSurvivalNeoadjuvantDocetaxelToxicTherapyLiposomesTumorEfficacyToxicityApoptosisCancersAnthracyclineIndicationsCardiotoxicityClinical trialExposurePeptideDrugEffectRelevanceStudyTreatmentCellsPlasma concentrationsDemonstrateSide effectsCancerSearchOutcomesDecreaseSignificantly
Cyclophosphamide10
  • The objective of this study was to determine the pCR rate in patients with stage III breast cancer treated with 4 cycles of TAC (docetaxel 75 mg/m 2 , doxorubicin 50 mg/m 2 , cyclophosphamide 500 mg/m 2 ) on day 1 before surgery. (elsevierpure.com)
  • Conclusion: Based on the pCR rate seen in this trial, docetaxel given concomitantly with AC (doxorubicin/cyclophosphamide) for 4 cycles does not appear to be superior to 4 cycles of AC as preoperative treatment for stage III breast cancer. (elsevierpure.com)
  • First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without. (slideplayer.com)
  • 2 First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer O'Shaughnessy J et al. (slideplayer.com)
  • We also collected surface wipe samples for cyclophosphamide, ifosfamide, and doxorubicin at the beginning of the work day before the chemotherapy drugs were unpacked and at the end of the work day after the last chemotherapy treatment was completed. (cdc.gov)
  • To evaluate tolerability and maintenance of dose intensity of 2 weekly treatment with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide (VDC/IE) in patients with advanced small round cell sarcomas including Ewing family tumours (EFT), desmoplastic small round cell tumours (DSRCT) and undifferentiated high grade round cell sarcomas (UHGRCS). (biomedcentral.com)
  • The Children's Oncology Group (COG) study, INT-0154, using a regimen of vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE), randomized patients to an increased treatment intensity by higher doses of cyclophosphamide and ifosfamide and a decreased length of treatment to 11 cycles over 30 weeks in the test arm compared with a standard 17 cycles over 48 weeks but with equivalent total drug doses in each arm. (biomedcentral.com)
  • She had been treated for her lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab during May-August 2012. (cdc.gov)
  • A combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment regimen for DLBCL. (news-medical.net)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
Vincristine1
  • The current European Ewing tumour Working Initiative of National Groups 1999 (EURO-EWING 99) study has enrolled over 3,200 patients in a study evaluating an intensive induction regimen (VIDE, vincristine, ifosfamide, doxorubicin and etoposide) and, in selected cohorts of randomized patients, high dose chemotherapy with stem cell rescue. (biomedcentral.com)
Cisplatin1
  • The addition of paclitaxel to cisplatin and doxorubicin following surgery and radiation was not associated with a significant improvement in RFS but was associated with increased toxicity. (nih.gov)
Chemotherapy8
  • Background: The use of preoperative chemotherapy for breast cancer has been demonstrated to result in similar disease-free survival (DFS) and overall survival (OS) as postoperative adjuvant chemotherapy. (elsevierpure.com)
  • The cholesterol-lowering drug atorvastatin (Lipitor) may help reduce the risk of heart failure in people with lymphoma who receive chemotherapy drugs called anthracyclines, results from a clinical trial suggest. (cancer.gov)
  • Chemotherapy with streptozocin (STZ) in combination with 5-FU or doxorubicin (Dox) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (pNEN). (cancerindex.org)
  • A chemotherapy drug called doxorubicin could lower the risk of sarcoma coming back for some people after surgery. (cancerresearchuk.org)
  • Research is continuing to try to improve the results of chemotherapy treatment for sarcoma. (cancerresearchuk.org)
  • These results indicate that in addition to systemic chemotherapy, an adjuvant nHA could be used as a carrier for intracellular delivery of DOX for prevention of tumor recurrence after surgical resection in an osteosarcoma. (lu.se)
  • Approval was based on results from the Phase III AURELIA study, which showed that adding bevacizumab to chemotherapy significantly improved progressive-free survival (PFS) and overall response rate (ORR). (medscape.com)
  • Cancers such as doxorubicin are commonly used in cancer leukaemia, colorectal, breast, lung, and so on are chemotherapy. (who.int)
Studied the effect of doxorubicin1
Paclitaxel1
Liposomal doxorubicin1
Conjugate1
  • Doxorubicin-tripeptide conjugate was then observed to clarify the target delivery by PEPT1 and the antitumor effect on human hepatocarcinoma in vivo and in vitro . (oncotarget.com)
Ifosfamide1
Hepatocellular carcinoma1
  • Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. (insa-lyon.fr)
Anticancer3
  • We can conclude that lyophilization of the liposomes encapsulating doxorubicin lead to marked stability for the liposomes when stored at 5°C. Moreover, the use of low energy diode laser for targeting anticancer drug to the tumor cells through the use of photosensitive sterically stabilized liposomes loaded with doxorubicin is a promising method. (biomedcentral.com)
  • Doxorubicin (DOX) is one of the most valuable anticancer drugs in the present clinical use. (biomedcentral.com)
  • We investigated the effect of doxorubicin (DOX), a DNA-damaging anticancer drug, on apoptosis and the expression of the mitochondrial NADH dehydrogenase 3 (MT-ND3) and cytochrome b (MT-CYB) in model CML cells showing imatinib resistance caused by Y253H mutation in the BCR-ABL1 gene (253) or culturing imatinib-sensitive (S) cells in increasing concentrations of imatinib (AR). (temple.edu)
Patients2
  • A phase I trial in prostate cancer indicated that nine out ten evaluable patients achieved disease stabilization through administration of zoptarelin doxorubicin. (wikipedia.org)
  • In contrast a survival advantage has been reported in the preliminary results from a further COG study of patients with localized EFT, AEWSOO31, randomizing between a standard three weekly schedule and an 'interval compressed' two weekly schedule of VDC/IE, the latter made possible by growth factor support[ 18 ]. (biomedcentral.com)
Antitumor3
  • Doxorubicin (DOX) is a commonly used anthracycline broad-spectrum antitumor antibiotic with strong antitumor effect and definite curative effect. (frontiersin.org)
  • In this study, we aim to explore the feasibility of a novel tumor target therapeutic strategy: Targeting PEPT1 to improve the antitumor efficacy of Doxorubicin in human HCC therapy. (oncotarget.com)
  • Guarantied process parameters are: DOXORUBICIN Antitumor drug Chemical. (farmavita.net)
Chemotherapeutic agents1
  • But the chemotherapeutic agents are relatively ineffective and result in many serious toxic and side effects. (oncotarget.com)
Cycles1
  • This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450 mg/m2 (165, 260, 325 mg/m2 doxorubicin equivalents, respectively) through intravenous infusion on Day 1 every 21 days for up to 6 cycles. (drugpatentwatch.com)
Lymphoma2
  • Their results suggest that R-CHOP followed by rituximab maintenance therapy offers the elderly mantle cell lymphoma patient with the greatest odds of treatment success. (lymphomainfo.net)
  • Lymphoma, a type of blood cancer, results from the uncontrolled proliferation of lymphocytes. (news-medical.net)
Survival5
  • In the past decade, several randomized trials and meta-analyses have displayed improvements in local control and overall survival with postmastectomy radiotherapy (PMRT) for locally advanced breast cancer, but have failed to report age-specific results. (oncolink.org)
  • In May 2017 the results were disclosed, showing that the drug did not extend overall survival nor did it improve the safety profile compared to doxorubicin. (wikipedia.org)
  • For people with lung cancer and medullary thyroid cancer whose tumors have changes in the RET gene, selpercatinib improved progression-free survival compared with other common treatments, according to new clinical trial results. (cancer.gov)
  • This move came after results from a phase III clinical trial found the drug did not improve survival for people with soft tissue sarcoma. (mskcc.org)
  • These collective efforts in diagnosis and treatment have resulted in great improvements in survival rates, which nonetheless continue to vary considerably by type of cancer and geographical region. (who.int)
Neoadjuvant1
  • 35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemothe. (oncolink.org)
Docetaxel1
  • Based on other trials, longer durations of therapy and/or sequencing of AC and docetaxel may result in a higher pCR rate. (elsevierpure.com)
Toxic3
  • The proposed method of action is that upon administration zoptarelin doxorubicin binds to the LHRH receptor and is subsequently internalized, concentrating the toxic doxorubicin within cancer cells and the small subset of normal tissues, as opposed to the completely systemic distribution observed with untargeted chemotherapeutics. (wikipedia.org)
  • Furthermore, the improvement of the toxic and side effect of Doxorubicin after conjugation was also evaluated by some biochemical tests. (oncotarget.com)
  • It proved to be applicable and successful for treatment of Ehrlich solid tumors implanted in mice and eliminated toxic side effects of doxorubicin. (biomedcentral.com)
Therapy3
  • Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy? (eurekaselect.com)
  • In this study, we constructed a nano-drug delivery system (NPF@DOX) targeting FAP to increase the therapeutic efficiency of synergistic chemo-photothermal therapy against OSCC.Methods: We utilized PEGylated nano-graphene oxide (NGO) to link doxorubicin (DOX) and fluorescently-labeled, FAP-targeted peptide chains via hydrogen bonding and π-π bonding to enhance the targeting capability of NPF@DOX. (doaj.org)
  • Based on the results of a recent clinical trial conducted at MSK, the FDA has granted olaratumab Breakthrough Therapy status. (mskcc.org)
Liposomes2
Tumor3
  • Additionally, the drug uptake efficiency in vitro, photo-thermal properties, release performance, and anti-tumor effects of NPF@DOX were evaluated and further demonstrated in vivo.Results: Data derived from FT-IR, UV-Vis, and TEM implied successful construction of the NPF@DOX nano-drug delivery system. (doaj.org)
  • TACE induced a reduction in tumor size mainly due to ischemia resulting from embolization 11 which expose tumor to acute hypoxia. (nature.com)
  • Results -Gelatinolytic bands were observed from the analysis of all tumor tissues and in most stromal tissues. (avma.org)
Efficacy1
  • If zafirlukast is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. (pdr.net)
Toxicity3
  • This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. (nih.gov)
  • Our results reveal that targeting PEPT1 may contribute to the efficient delivery of Doxorubicin to hepatocarcinoma cells and the reduction of drug toxicity. (oncotarget.com)
  • Despite of being highly effective, the use of Doxorubicin has many limitations due to the significant toxicity and side effects occurred during and after HCC treatment. (oncotarget.com)
Apoptosis2
  • Columbianadin attenuates doxorubicin-induced cardiac injury, oxidative stress, and apoptosis via Sirt1/FOXO1 signaling pathway. (bvsalud.org)
  • Oxidative stress and apoptosis contribute to the pathological basis of doxorubicin (DOX)-induced cardiotoxicity . (bvsalud.org)
Cancers1
  • Doxorubicin is a traditional chemotherapeutic agent for a wide variety of cancers. (oncotarget.com)
Anthracycline2
  • Our results suggest that anthracycline-induced cytotoxicity is cell cycle dependent and is mediated, at least in part, by disturbance of the regulation of p34cdc2/cyclin B1 complex, thus leading to G2/M phase arrest. (aspetjournals.org)
  • DOXOrubicin is an anthracycline. (medscape.com)
Indications1
Cardiotoxicity2
  • The specific targeting of the doxorubicin to LHRH receptor bearing cells is also proposed to reduce the cardiotoxicity observed in the administration of unconjugated doxorubicin. (wikipedia.org)
  • Our results demonstrated that CBN might be used to treat DOX-related cardiotoxicity . (bvsalud.org)
Clinical trial2
  • Promising results have been reported from a phase II clinical trial for ovarian cancer and endometrial cancer. (wikipedia.org)
  • New clinical trial results mark a pivotal moment following years of little progress, bladder cancer experts believe. (cancer.gov)
Exposure2
  • Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like zafirlukast can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. (pdr.net)
  • Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. (medscape.com)
Peptide1
  • Zoptarelin doxorubicin (developmental code names AEZS-108, AN-152) consists of doxorubicin linked to a small peptide agonist to the luteinizing hormone-releasing hormone (LHRH) receptor. (wikipedia.org)
Drug1
  • To overcome this, we demonstrate that doxorubicin (DOX), a cornerstone drug used for osteosarcoma treatment, shows reversible accretion to hydroxyapatite (HA) of both nano (nHA) and micro (mHA) size. (lu.se)
Effect5
  • The objective of study was to evaluate the effect of n-butanol fraction (NBF) and ethyl acetate fraction (EAF) of flowers of Butea monosperma (BM) against doxorubicin (DOX) induced nephrotic syndrome (NS). (omicsonline.org)
  • apalutamide will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • darolutamide will increase the level or effect of doxorubicin by Other (see comment). (medscape.com)
  • enzalutamide will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • erdafitinib will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. (medscape.com)
Relevance1
  • Conclusion and Clinical Relevance -Results indicated that at the dose used, neither the concentrations of fatty acids in skin or plasma nor a decrease in the production of inflammatory eicosanoids was a major factor involved in the mechanism of action in dogs with atopy that responded to fatty acid supplementation. (avma.org)
Study5
  • Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted. (nih.gov)
  • The incidence is slightly higher in African Americans than in Caucasians (data from the National Cancer Institute [NCI] Surveillance, Epidemiology, and End Results [SEER] Study Pediatric Monograph, 1975-1995). (medscape.com)
  • Preliminary results from a study using a combination of VELCADE with Doxil showed high response rates (disease reduction). (drugpatentwatch.com)
  • But results of a study suggest that, for many, combining the targeted therapies vemurafenib (Zelboraf) and cobimetinib (Cotellic) may substantially delay, or even eliminate, the need for these treatments. (cancer.gov)
  • Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of. (lymphomainfo.net)
Treatment5
  • Therefore, we think that PTP1B may play an important role in the development of heart failure induced by doxorubicin and can be used as a potential target for the treatment of heart failure. (frontiersin.org)
  • Results showed that TIGAR was increased and relocated to the nucleus after epirubicin or hypoxia treatment in cancer cells. (nature.com)
  • In contrast, Dox treatment was found to induced cyclin B1 accumulation as a result of stimulating its synthesis and inhibiting its degradation. (aspetjournals.org)
  • The study's lead investigator says the results are "unprecedented" for this rare disease, which currently has very limited treatment options. (mskcc.org)
  • This treatment, together with the underlying hematologic disease, resulted in an immunocompromised condition. (cdc.gov)
Cells2
  • The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. (nature.com)
  • Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. (aspetjournals.org)
Plasma concentrations1
  • Moderate) Concomitant use of dihydrocodeine with zafirlukast may increase dihydrocodeine plasma concentrations, resulting in greater metabolism by CYP2D6, increased dihydromorphine concentrations, and prolonged opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. (pdr.net)
Demonstrate1
  • The genotoxicity results clearly demonstrate that hydroxyurea does not directly bind DNA and is not mutagenic. (cdc.gov)
Side effects1
Cancer6
  • We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer. (nih.gov)
  • Zoptarelin doxorubicin was invented by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami. (wikipedia.org)
  • Phase II trials have also been undertaken for prostate, breast and bladder cancer, although no results for these trials have been reported in peer-reviewed literature. (wikipedia.org)
  • 6 FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer Joensuu H et al. (slideplayer.com)
  • Anthracyclines, such as doxorubicin, are used to treat many types of cancer. (cancer.gov)
  • Existing approaches to managing the prices of cancer medicines have not resulted in outcomes that meet policy and economic objectives. (who.int)
Search3
  • Click "SGD search" to view all alleles in search results. (yeastgenome.org)
  • The export option will allow you to export the current search results of the entered query to a file. (temple.edu)
  • To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. (temple.edu)
Outcomes1
  • However, with an adeq battery of necf expsre blmarkers, prospective studies of en- vironmental effects on pregnancy outcomes might be possible. (cdc.gov)
Decrease1
  • Proponents also claim that coenzyme Q10 can decrease the muscle symptoms that can result from taking statins. (msdmanuals.com)
Significantly1
  • The results showed that a total of 278 proteins with significant changes were identified by quantitative proteomic analysis, of which 118 proteins were significantly upregulated and 160 proteins were significantly downregulated in myocardial tissue. (frontiersin.org)